Single User License
INR 100470
Site License
INR 200940
Corporate User License
INR 301410

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Amicus Therapeutics, Inc.-Product Pipeline Review-2015

Amicus Therapeutics, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07265CDB
  • |
  • Pages: 54
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Amicus Therapeutics, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Amicus Therapeutics, Inc.-Product Pipeline Review-2015', provides an overview of the Amicus Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amicus Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Amicus Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Amicus Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Amicus Therapeutics, Inc.'s pipeline products

Reasons To Buy

Evaluate Amicus Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Amicus Therapeutics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Amicus Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Amicus Therapeutics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amicus Therapeutics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Amicus Therapeutics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Amicus Therapeutics, Inc. Snapshot 6

Amicus Therapeutics, Inc. Overview 6

Key Information 6

Key Facts 6

Amicus Therapeutics, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Amicus Therapeutics, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Combination Treatment Modalities 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Amicus Therapeutics, Inc.-Pipeline Products Glance 14

Amicus Therapeutics, Inc.-Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Amicus Therapeutics, Inc.-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Amicus Therapeutics, Inc.-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Amicus Therapeutics, Inc.-Drug Profiles 18

migalastat hydrochloride 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

(migalastat hydrochloride + agalsidase alfa) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

duvoglustat hydrochloride + alglucosidase alfa 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

(duvoglustat hydrochloride + ATB-200) 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

afegostat tartrate 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

afegostat tartrate + ERT 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

AT-3375 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ATB-200 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Chaperone-ERT Combinations 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

laronidase + chaperone 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

migalastat hydrochloride + Enzyme Replacement Therapy Biobetter 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Recombinant Enzyme for Lysosomal Storage Disorder 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule for Neurodegenerative Diseases 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Amicus Therapeutics, Inc.-Pipeline Analysis 35

Amicus Therapeutics, Inc.-Pipeline Products by Target 35

Amicus Therapeutics, Inc.-Pipeline Products by Route of Administration 36

Amicus Therapeutics, Inc.-Pipeline Products by Molecule Type 37

Amicus Therapeutics, Inc.-Pipeline Products by Mechanism of Action 38

Amicus Therapeutics, Inc.-Recent Pipeline Updates 39

Amicus Therapeutics, Inc.-Dormant Projects 45

Amicus Therapeutics, Inc.-Company Statement 46

Amicus Therapeutics, Inc.-Locations And Subsidiaries 52

Head Office 52

Other Locations & Subsidiaries 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

Amicus Therapeutics, Inc., Key Information 6

Amicus Therapeutics, Inc., Key Facts 6

Amicus Therapeutics, Inc.-Pipeline by Indication, 2015 8

Amicus Therapeutics, Inc.-Pipeline by Stage of Development, 2015 9

Amicus Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

Amicus Therapeutics, Inc.-Combination Treatment Modalities in Pipeline, 2015 11

Amicus Therapeutics, Inc.-Partnered Products in Pipeline, 2015 12

Amicus Therapeutics, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 13

Amicus Therapeutics, Inc.-Pre-Registration, 2015 14

Amicus Therapeutics, Inc.-Phase III, 2015 15

Amicus Therapeutics, Inc.-Phase II, 2015 16

Amicus Therapeutics, Inc.-Preclinical, 2015 17

Amicus Therapeutics, Inc.-Pipeline by Target, 2015 35

Amicus Therapeutics, Inc.-Pipeline by Route of Administration, 2015 36

Amicus Therapeutics, Inc.-Pipeline by Molecule Type, 2015 37

Amicus Therapeutics, Inc.-Pipeline Products by Mechanism of Action, 2015 38

Amicus Therapeutics, Inc.-Recent Pipeline Updates, 2015 39

Amicus Therapeutics, Inc.-Dormant Developmental Projects,2015 45

Amicus Therapeutics, Inc., Subsidiaries 52

List of Figures

Amicus Therapeutics, Inc.-Pipeline by Top 10 Indication, 2015 8

Amicus Therapeutics, Inc.-Pipeline by Stage of Development, 2015 9

Amicus Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

Amicus Therapeutics, Inc.-Combination Treatment Modalities in Pipeline, 2015 11

Amicus Therapeutics, Inc.-Pipeline by Top 10 Target, 2015 35

Amicus Therapeutics, Inc.-Pipeline by Top 10 Route of Administration, 2015 36

Amicus Therapeutics, Inc.-Pipeline by Top 10 Molecule Type, 2015 37

Amicus Therapeutics, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Amicus Therapeutics, Inc.; Amicus Therapeutics, Inc. - Key Therapeutics; Amicus Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Amicus Therapeutics, Inc. - News; Amicus Therapeutics, Inc. - Latest Updates; Amicus Therapeutics, Inc. - Pipeline; Amicus Therapeutics, Inc. - Discontinued/Dormant Projects

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]